News

LEXINGTON, Ky. (Aug. 4, 2020) – The University of Kentucky Markey Cancer Center has announced that Krystle Kuhs, Ph.D., M.P.H., will serve as co-leader of its Cancer Prevention and Control Research Program. Kuhs will co-lead the program with University of Kentucky College of Public Health Associate Professor Jerod Stapleton, Ph.D., who joined the university in November 2019.

The COVID-19 pandemic and social distancing requirements have affected every aspect of our lives, often causing anxiety, uncertainty and disrupted routines. In a recent poll by the Kaiser Family Foundation, nearly half (45%) of Americans reported that their mental health has been negatively impacted due to worry and stress over the virus. Such stressful situations, especially when they last for a long time, can lead to harmful health behaviors like increased alcohol consumption and trouble sleeping.

LEXINGTON, Ky. (July 31, 2020) – During his chemotherapy treatments, Scott Storey got used to avoiding cold drinks and foods. The regimen he was on, FOLFOX, includes the drug oxaliplatin, which is known to cause “cold dysesthesia” in some patients. It’s a hypersensitivity to the presence of cold that can trigger side effects such as peripheral neuropathy, jaw spasms, shortness of breath and more.

This peculiar fact – and a serendipitous meeting with a stranger – proved to be a lifeline for the retired Air Force veteran.

LEXINGTON, Ky.  (July 30, 2020) —The COVID-19 pandemic brought many things to a screeching halt and continues to impact our daily lives. However, important research at the University of Kentucky’s Sanders-Brown Center on Aging (SBCoA) is continuing under extreme caution and deep dedication.

“It can’t wait,” said Dr. Greg Jicha, a neurologist at SBCoA.  

LEXINGTON, Ky. (July 29, 2020) — Alzheimer’s disease (AD) is the most common form of dementia among the elderly and currently there is no cure for the disease. The hallmarks of AD are the Aβ plaques and tau tangles found throughout the patient’s brain. For the past several decades, much of the work to find a treatment for AD has been focused on eliminating those dreaded Aβ plaques, by assuming that memory could be restored by removing the plaques.

It is with great sorrow that I share with you the passing of two vital members of the UK College of Medicine’s history, both of whom were former chairs.

Ward O. Griffen, MD, PhD, former chair of the department of surgery, passed away Tuesday, July 21, at the age of 92, and Jacqueline Noonan, MD, former chair of the department of pediatrics, died on July 23 at the age of 91. The College of Medicine community will miss both deeply.

Ward O. Griffen, MD, PhD

LEXINGTON, Ky. (July 28, 2020) – For the fifth consecutive year, the University of Kentucky Albert B. Chandler Hospital at UK HealthCare has been named the No. 1 hospital in Kentucky and the Bluegrass Region by the 2020-2021 Best Hospitals rankings and ratings from U.S. News & World Report.

For the fourth straight year, the University of Kentucky Markey Cancer Center has earned a top 50 national ranking for cancer care, this year climbing to No. 29.

Throughout the summer the University of Kentucky College of Medicine has been part of a University-wide pilot program aiming to help boost resumes and build important skills for both UK and non-UK students.

The Summer Badge Program is not your average summer school. The program provides an opportunity for learners to complete courses and earn digital badges, regardless of their current major, with the badges certifying competency in a specific skill.

LEXINGTON, Ky. (July 24, 2020) — During his chemotherapy treatments, Scott Storey got used to avoiding cold drinks and foods. The regimen he was on, FOLFOX, includes the drug oxaliplatin, which is known to cause “cold dysesthesia” in some patients. It’s a hypersensitivity to the presence of cold that can trigger side effects such as peripheral neuropathy, jaw spasms, shortness of breath and more.

This peculiar fact – and a serendipitous meeting with a stranger – proved to be a lifeline for the retired Air Force veteran.

LEXINGTON, Ky. (July 24, 2020) — Dr. Reshma Ramlal of the University of Kentucky Markey Cancer Center was recently named the 2020 Lexington Woman of the Year by the Leukemia & Lymphoma Society.

LEXINGTON, Ky. (July 22, 2020) — Early this spring, University of Kentucky virologist Rebecca Dutch answered some of our initial questions about COVID-19 and SARS-CoV-2, the virus that causes the disease. We asked her to take another look at the coronavirus pandemic.

LEXINGTON, Ky. (July 21, 2020) — A $3.2 million grant will support University of Kentucky College of Medicine research that could pave the way for a treatment for traumatic brain injury (TBI).

LEXINGTON, Ky. (July 14, 2020) — A new study by researchers at the University of Kentucky identifies a novel function of the enzyme spermine synthase (SMS) to facilitate colorectal cancer growth.

SMS is an enzyme that produces spermine from spermidine, which has been shown to be important for cell growth. However, excessive accumulation of spermidine can have harmful effects on cell viability. How cancer cells maintain a relatively high level of spermidine but below the toxic threshold to facilitate tumor growth is not well understood.

A University of Kentucky College of Medicine researcher has been awarded $1.9 million to continue research examining molecular pathogenesis of Noonan-like syndrome. Emilia Galperin, Ph.D., professor in the Department of Molecular & Cellular Biochemistry, was awarded a prestigious R35 Maximizing Investigator’s Research Award Grant from the National Institute of General Medical Sciences that will fund her lab’s research over the next five years. Normal human cell growth is controlled by complex signaling pathways, and errors in these signal transmissions can have serious consequences inclu

The long-running study on aging and brain health at the University of Kentucky’s Sanders-Brown Center on Aging (SBCoA) Alzheimer’s Disease Center has once again resulted in important new findings – highlighting a complex and under-recognized form of dementia. The work was recently published in The Journal of the American Medical Association (JAMA): Neurology. “One of the things that we’ve learned in the last decade or so is that a lot of people that we think have dementia from Alzheimer’s disease, actually don’t.

Dr. Daniel Moore, from the University of Kentucky College of Medicine’s Department of Ophthalmology and Visual Sciences, recently conducted a study looking at the frequency and use of racial and ethnic data in ophthalmology literature published throughout 2019. He wrote an article outlining his findings which was published in The Journal of the American Medical Association: Ophthalmology. Moore says the description of racial and ethnic data in human trials is relatively unregulated which can lead to confusion and inconsistent reporting.

Recent lab studies by chemists at the Max Planck Institute of Colloids and Interfaces (Potsdam, Germany) in close collaboration with virologists at Freie Universität Berlin have shown that extract from the medicinal plant Artemisia annua, also known as Sweet Wormwood, is active against SARS-CoV-2, the virus that has caused the COVID-19 pandemic. The new potential treatment has been added to the University of Kentucky’s innovative clinical trial for experimental COVID-19 therapies, which was launched by leaders from UK’s Markey Cancer Center, College of Medicine and College of Pharmacy in May.

The Building Interdisciplinary Research Careers in Women’s Health (BIRCWH) Program in the University of Kentucky College of Medicine is accepting applications to fill one position. Applications are due July 17, 2020.

LEXINGTON, Ky. (June 18, 2020) — Alpacas Big Boy, Blue Eyes and Emperor may hold the key to combating COVID-19. Their antibodies could offer a defense against SARS-CoV-2, the virus that causes the disease.

University of Kentucky College of Medicine researchers are using the special antibodies made by alpacas, called nanobodies, to help understand the novel coronavirus and potentially develop a treatment that could protect people from being infected. 

The University of Kentucky College of Medicine and UK HealthCare have launched a new clinical trial designed to assess the prevalence of COVID-19 in central and eastern Kentucky.